drugset / Trial / NCT00042458

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

NCT00042458

Phase 3 Completed 296 enrolled AstraZeneca
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This is a randomized, triple-blind, placebo-controlled, multicenter study to investigate the safety of pramlintide treatment using pramlintide dose-titration coupled with insulin adjustments in subjects with type 1 diabetes who are actively trying to improve their glycemic control.

Timeline

Start
2002-04
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pramlintide Peptide 30 ug Subcutaneous
Comparator Pramlintide Peptide 60 ug Subcutaneous